
Plasma Protein Therapeutics Market Report and Forecast 2025-2034
Description
The global plasma protein therapeutics market size was valued at USD 30.40 Billion in 2024, driven by increasing demand for plasma protein therapies across the globe. The market size is anticipated to grow at a CAGR of 6.10% during the forecast period of 2025-2034 to achieve a value of USD 54.96 Billion by 2034.
Plasma Protein Therapeutics: Introduction
Plasma-derived therapies play a crucial role in enhancing the quality of life for individuals by replacing missing or deficient proteins. These therapies are often a lifeline for patients who rely on them, necessitating regular infusions or injections throughout their lifetimes. The conditions treated by plasma protein therapies are typically categorized as rare diseases since they affect a relatively small percentage of the population, with many being genetic and chronic in nature.
Global Plasma Protein Therapeutics Market Analysis
The market is experiencing robust growth driven by the increase in demand for plasma protein therapies, particularly for conditions like hemophilia and Primary Immunodeficiency Disorders (PID), along with various other medical conditions. Novel drug therapies have gained high acceptance and accessibility, further fuelling the market expansion. Moreover, there is a significant increase in research and development efforts as well, particularly in the field of hemophilia therapy, contributing to the global plasma protein therapeutics market growth.
Additionally, the rising prevalence of autoimmune disorders has further amplified the demand for plasma protein therapeutics. Immunoglobulins are taking the lead in the product landscape, underscoring their importance in treating various medical conditions.
Global Plasma Protein Therapeutics Market Segmentations
“global plasma protein therapeutics market and forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The market is experiencing substantial growth driven by factors such as continuous product innovations in the field of plasma protein therapeutics adding options to existing treatment options and improving patient outcomes. The market is also driven by the increasing prevalence of autoimmune disorders and genetic disorders worldwide resulting in increased demand for these therapies, further propelling the plasma protein therapeutics market demand. The rising geriatric population that often requires such treatments has contributed to the market growth as well.
Government initiatives aimed at improving healthcare accessibility and affordability also play a pivotal role in fuelling the market's upward trajectory. Moreover, there is an escalating demand for albumin and an increased use of plasma proteins in pharmaceuticals, underlining their critical role in various medical treatments. Furthermore, the rising usage of immunoglobulin therapies has added to the market's overall growth, making the market a vibrant and evolving sector within the healthcare sector.
Global Plasma Protein Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Plasma Protein Therapeutics: Introduction
Plasma-derived therapies play a crucial role in enhancing the quality of life for individuals by replacing missing or deficient proteins. These therapies are often a lifeline for patients who rely on them, necessitating regular infusions or injections throughout their lifetimes. The conditions treated by plasma protein therapies are typically categorized as rare diseases since they affect a relatively small percentage of the population, with many being genetic and chronic in nature.
Global Plasma Protein Therapeutics Market Analysis
The market is experiencing robust growth driven by the increase in demand for plasma protein therapies, particularly for conditions like hemophilia and Primary Immunodeficiency Disorders (PID), along with various other medical conditions. Novel drug therapies have gained high acceptance and accessibility, further fuelling the market expansion. Moreover, there is a significant increase in research and development efforts as well, particularly in the field of hemophilia therapy, contributing to the global plasma protein therapeutics market growth.
Additionally, the rising prevalence of autoimmune disorders has further amplified the demand for plasma protein therapeutics. Immunoglobulins are taking the lead in the product landscape, underscoring their importance in treating various medical conditions.
Global Plasma Protein Therapeutics Market Segmentations
“global plasma protein therapeutics market and forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Immunoglobulin
- Albumin
- Plasma Derived Factor
- Others
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Primary Immunodeficiencies
- Other Applications
- Hospitals
- Home Care
- ASCs
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market is experiencing substantial growth driven by factors such as continuous product innovations in the field of plasma protein therapeutics adding options to existing treatment options and improving patient outcomes. The market is also driven by the increasing prevalence of autoimmune disorders and genetic disorders worldwide resulting in increased demand for these therapies, further propelling the plasma protein therapeutics market demand. The rising geriatric population that often requires such treatments has contributed to the market growth as well.
Government initiatives aimed at improving healthcare accessibility and affordability also play a pivotal role in fuelling the market's upward trajectory. Moreover, there is an escalating demand for albumin and an increased use of plasma proteins in pharmaceuticals, underlining their critical role in various medical treatments. Furthermore, the rising usage of immunoglobulin therapies has added to the market's overall growth, making the market a vibrant and evolving sector within the healthcare sector.
Global Plasma Protein Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- CSL Limited
- Baxter International
- Bio Products Laboratory Ltd
- Octapharma AG
- Kedrion, SpA
- Becton, Dickinson and Company
- Takeda Pharmaceutical
- Grifols, S.A.
- ADMA Biologics Inc
- Bayer AG
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Plasma Protein Therapeutics Market Overview
- 3.1 Global Plasma Protein Therapeutics Market Historical Value (2018-2024)
- 3.2 Global Plasma Protein Therapeutics Market Forecast Value (2025-2034)
- 4 Global Plasma Protein Therapeutics Market Landscape
- 4.1 Global Plasma Protein Therapeutics: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Plasma Protein Therapeutics: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Applications
- 5 Global Plasma Protein Therapeutics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Plasma Protein Therapeutics Market Segmentation
- 6.1 Global Plasma Protein Therapeutics Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Immunoglobulin
- 6.1.3 Albumin
- 6.1.4 Plasma Derived Factor
- 6.1.5 Others
- 6.2 Global Plasma Protein Therapeutics Market by Applications
- 6.2.1 Market Overview
- 6.2.2 Hemophilia
- 6.2.3 Idiopathic Thrombocytopenic Purpura
- 6.2.4 Primary Immunodeficiencies
- 6.2.5 Other Applications
- 6.3 Global Plasma Protein Therapeutics Market by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Home Care
- 6.3.4 ASCs
- 6.4 Global Plasma Protein Therapeutics Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Plasma Protein Therapeutics Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Global Protein Therapeutics Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Plasma Protein Therapeutics Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Plasma Protein Therapeutics Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Plasma Protein Therapeutics Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 CSL Limited
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Baxter International
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Bio Products Laboratory Ltd
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Octapharma AG
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Kedrion, SpA
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Becton, Dickinson and Company
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Takeda Pharmaceutical
- 17.7.1 Product Portfolio
- 17.7.2 Demographic Reach and Achievements
- 17.7.3 Mergers and Acquisitions
- 17.7.4 Certifications
- 17.8 Grifols, S.A.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 ADMA Biologics Inc
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Bayer AG
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.